A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Part of paid clinical trials in West Hollywood, California.
- Sponsor
- C4 Therapeutics, Inc.
- Study ID
- NCT07284758
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cemsidomide — DRUGdosed orally (PO) once a day (QD) 14 days on/14 days off for each 28-day cycle
- Dexamethasone — DRUGdosed PO once a week (QW) on Days 1, 8, 15, and 22 for each 28-day cycle
Study Details
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Key Dates
- Start date
- Feb 18, 2026
- Status verified
- Mar 2026
- Primary completion
- Mar 31, 2030
- Completion
- Mar 31, 2030
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Cemsidomide + Dexamethasone:Participants receive cemsidomide plus dexamethasone during a 28-day treatment cycle, and will continue to receive treatment until the participant meets one of the discontinuation criteria.
Primary Outcome Measure
Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC) [ Time Frame: up to approximately 43 months ]
Central Contacts
- Study Medical Officer(617) 231-0700
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Berenson Cancer Center | West Hollywood | California | 90069 | James Berenson, MD |
| START Midwest | Grand Rapids | Michigan | 49546 | Andrew Sochacki, MD |
| START San Antonio | San Antonio | Texas | 78229 | Kyriakos Papadopoulos, MD |
Find similar trials in West Hollywood, CA
By condition
By specialty
Related Studies
- Collection of Tissue Samples for Cancer ResearchRecruiting · National Cancer Institute (NCI) · Sacramento, California
- Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple MyelomaPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPHASE2 · Recruiting · American Society of Clinical Oncology · Birmingham, Alabama
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsPHASE1 · Recruiting · Oncotherapeutics · Alhambra, California